Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Velcade recommended for approval in Europe

Jan. 27, 2004

EntreMed identifies peptide fragment of tissue factor pathway inhibitor

Jan. 27, 2004

European approval recommended for Lysodren

Jan. 27, 2004

CPMP recommends extension of Paxene indications

Jan. 27, 2004

CR-4: a novel tyrosine kinase inhibitor active against ALL and AML cell lines

Jan. 27, 2004

Onyvax and Mayo Clinic to develop cancer vaccines for ovarian cancer

Jan. 26, 2004

Zevalin radioimmunotherapy receives European approval

Jan. 26, 2004

CytoGenix and Baylor to test aerosol gene silencing agent on mouse lung cancer

Jan. 23, 2004

OSI commences rolling NDA submission for Tarceva for NSCLC

Jan. 23, 2004

PI-88 enters phase II melanoma trial

Jan. 23, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...